Compare SharkNinja Inc. Ordinary Shares (SN) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SharkNinja Inc. Ordinary Shares vs Tango Therapeutics Inc. — how do they compare? SharkNinja Inc. Ordinary Shares trades at $186 (market cap $26.60B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: SharkNinja Inc. Ordinary Shares is far larger — about 7.1× Tango Therapeutics Inc.'s market cap, and SharkNinja Inc. Ordinary Shares is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold SharkNinja Inc. Ordinary Shares for 3 Days and Tango Therapeutics Inc. for 0 Days on average.
| SN | TNGX | |
|---|---|---|
Market Cap | $26.60B | $3.75B |
Volume | 1,030,578 | 9,619,106 |
Sector | Consumer Cyclical | Health |
52-Week High | $192.86 | $32.90 |
52-Week Low | $84.57 | $7.50 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $26.73B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SharkNinja (SN) trades at $188.80, down 0.62% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, 10.06% net margin, and robust cash flow growth. Recent product launches including new vacuum and kitchen systems highlight ongoing innovation. Analyst sentiment remains overwhelmingly positive with 91% buy ratings and a $202.18 consensus target.
SN presents a compelling growth story with strong profitability and product momentum, though elevated P/E of 38.5 suggests premium valuation. Key risks include consumer spending sensitivity and competitive pressures in home appliances. The stock's proximity to resistance at $192 requires monitoring for breakout confirmation.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About SharkNinja Inc. Ordinary Shares
SharkNinja designs and sells small household appliances under the Shark and Ninja brands. Its products include cleaning appliances, kitchen and beverage appliances, food preparation products, and beauty and home-environment devices.
Read more on SN →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
